Roche eyes targets to counter patent expiries
Roche warned its earnings could grow more slowly this year because of patent expiries, costly product launches and an unprecedented number of new drugs in expensive late-stage trials. The Swiss
Roche warned its earnings could grow more slowly this year because of patent expiries, costly product launches and an unprecedented number of new drugs in expensive late-stage trials. The Swiss